Cutamesine (SA4503) Protects Retinal Ganglion Cells in an Ocular Hypertension Model of Glaucoma Determined Using Detection of Apoptosing Retinal Cells Technology and RBPMS Cell Marker
Sharif N.A., Takashi O., Taniguchi T., Sasaoka M., Guo L., Choi S., Luong V., Cordeiro M.F.
View publication
-
Therapeutic Area
Back of the eye (BOTE)
-
Categories
Preclinical development
-
Affiliations
Ophthalmology Innovation Center, Santen Inc., Emeryville, California, USA; Institute of Ophthalmology, University College London (UCL), London, United Kingdom; Imperial College of Science and Technology, St. Mary's Campus, London, United Kingdom; Eye-ACP Duke-National University of Singapore Medical School, Singapore, Singapore; Singapore Eye Research Institute (SERI), Singapore, Singapore; Department of Pharmacy Sciences, Creighton University, Omaha, Nebraska, USA; Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, Texas, USA; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas, USA; Global Research and Development, Nanoscope Therapeutics Inc., Dallas, Texas, USA; Ophthalmology Innovation Center, Santen Pharmaceutical Co., Ltd., Nara, Japan; Novai Ltd., Reading, United Kingdom